These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 25088125)

  • 1. Atrial fibrillation - new frontiers in anticoagulation.
    Thomas R; Page PL; Mitchell AR
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):45-9. PubMed ID: 25088125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
    Lane DA; Wood K
    Circulation; 2015 Apr; 131(16):e412-5. PubMed ID: 25901074
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
    Hellwig T; Gulseth M
    Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Improvements in oral anticoagulant therapy for atrial fibrillation].
    Briongos Figuero S; García Santos-Gallego C; Badimón JJ
    Med Clin (Barc); 2013 Dec; 141(11):487-93. PubMed ID: 23597953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence.
    Kopecky S
    Am J Cardiovasc Drugs; 2012 Oct; 12(5):287-94. PubMed ID: 22946769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
    Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
    Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
    [No Abstract]   [Full Text] [Related]  

  • 9. Target-specific oral anticoagulants: practice issues for the clinician.
    Plitt A; Giugliano RP
    Hosp Pract (1995); 2014 Aug; 42(3):48-61. PubMed ID: 25255406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral anticoagulants for stroke prevention in atrial fibrillation.
    Senoo K; Lane DA; Lip GY
    Curr Probl Cardiol; 2014 Sep; 39(9):319-44. PubMed ID: 25194766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
    Truffa AA; Lopes RD; Newby LK
    Postgrad Med; 2013 Mar; 125(2):146-57. PubMed ID: 23816780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
    Contractor T; Levin V; Martinez MW; Marchlinski FE
    Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching between oral anticoagulants.
    Strasser KM; Qasem A; Madhusudhana S
    Hosp Pract (1995); 2014 Aug; 42(3):68-74. PubMed ID: 25255408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
    Turagam MK; Velagapudi P; Bongu NR; Kocheril AG
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):79-86. PubMed ID: 25088126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New oral anticoagulants for atrial fibrillation: a neurologist's view].
    van Dijk EJ; Koudstaal PJ; Roos YB; Brouwers PJ; Kappelle LJ
    Ned Tijdschr Geneeskd; 2012; 156(39):A5283. PubMed ID: 23009824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP; Halperin JL
    Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
    Ezekowitz MD; Kent AP
    Circulation; 2014 Oct; 130(17):1505-14. PubMed ID: 25332278
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.